RenovoRx, Inc. (RNXT) stock analysis
Close on Nov 11, 2026Market cap $55.06MP/E –Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Weak6 of 30 checks passed
RenovoRx passes 6 of the 30 checks behind our score; 16 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 1/6
- Past performance
- 0/6
- Financial health
- 5/6
- Dividend
- 0/6
What stands out
No debt
RenovoRx has no borrowings on its latest balance sheet.
Interest well covered
No meaningful interest expense to cover.
Debt covered by cash flow
There is no debt to cover.
Guidance raised
RenovoRx raised its full-year 2026 revenue outlook on Aug 13, 2026.
What to watch
Margin of safety under 20%
The price is 163% above fair value, so there is no margin of safety.
Trading above fair value
The share price of $1.22 is above our fair value estimate of $0.46.
Return on equity under 15%
Return on equity was -150% over the last twelve months and averaged -520% over five years; we look for 15% on both.
Elevated bankruptcy risk
The Altman Z-score is -0.01; above 3 is the safe zone and below 1.8 the distress zone.
Valuation0/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B above the industry
RenovoRx's price-to-book of 5.93 is above the Surgical, Medical, and Dental Instruments and Supplies median of 3.20.
Trading above fair value
The share price of $1.22 is above our fair value estimate of $0.46.
Margin of safety under 20%
The price is 163% above fair value, so there is no margin of safety.
Growth1/6
Revenue growth over 3 years
Needs three years of positive revenue.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growth against the industry
Needs revenue for this year and last.
Guidance raised
RenovoRx raised its full-year 2026 revenue outlook on Aug 13, 2026.
Gross margin trend
This company does not report gross profit.
Past performance0/6
Return on equity under 15%
Return on equity was -150% over the last twelve months and averaged -520% over five years; we look for 15% on both.
Return on invested capital
Needs operating income and invested capital.
Return on equity below the industry
RenovoRx's return on equity of -150% is below the Surgical, Medical, and Dental Instruments and Supplies median of -32.4%.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin against its history
Needs five years of revenue and net income.
Net margin below the industry
RenovoRx's net margin of -469% is below the Surgical, Medical, and Dental Instruments and Supplies median of -14.1%.
Financial health5/6
No debt
RenovoRx has no borrowings on its latest balance sheet.
Debt not rising
With no debt today, leverage cannot have risen.
Debt covered by cash flow
There is no debt to cover.
Interest well covered
No meaningful interest expense to cover.
Short-term assets cover short-term debts
Current assets are 5.65 times current liabilities.
Elevated bankruptcy risk
The Altman Z-score is -0.01; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
RenovoRx has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itOur estimate per share
$0.46
The share price is 163% above this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| P/B | 3.7× | 4.2× | 3.2× | $0.75 | 50% |
| P/S | 2.8× | – | 2.8× | $0.17 | 50% |
| Fair value | $0.46 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/B at month end
- Own 5-year median 4.2
- Surgical, Medical, and Dental Instruments and Supplies median 3.2
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
High risk
- Average value traded per day
- $565.74K
- Value traded per 1% price move
- $169.51K
Downside
High risk
- Typical loss in a bad month
- 33.0%
- Volatility (annualized)
- 85%
- Sharpe ratio, 1 year
- 0.21
- Beta to the S&P 500 (5Y)
- 1.32
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +2511.6% | – | – | – | |
| Gross profit | +1751.2% | – | – | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 29.7% | -225.6% | |
| Return on assets | – | – | -137.8% | |
| Current ratio | – | 0.47 | 4.02 | |
| Capex to revenue | – | – | 0.2% | |
| Diluted shares | – | 2M | 35M |
Cash use needs five years of cash flow figures
RenovoRx does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -994.5% | 0.14× | 1.64× | -225.6% |
| FY2024 | -20497.7% | 0.01× | 1.28× | -235.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero-$11.17M
- Cash generatingOperating cash flow above zero-$10.97M
- Return on assets improvedROA up on the prior year-601.2% → -137.6%
- Earnings backed by cashOperating cash flow above net income-$10.97M vs -$11.17M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.10 → 4.02
- No dilutionShare count did not rise22M → 35M
- Gross margin improvedGross margin up on the prior year100.00% → 70.88%
- More efficientAsset turnover rose0.03 → 0.14
See a number that looks wrong?